UNSPSC 51282203: Flomoxef

This classification denotes a cephalosporin antibiotic with the molecular formula C15H18F2N6O7S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V9E5U5XF42, chemically known as (-)-(6r,7r)-7-(2-((difluoromethyl)thio)acetamido)-3-(((1-(2-hydroxyethyl)-1h-tetrazol-5-yl)thio)methyl)-7-methoxy-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid but generally known as flomoxef, which bears US NIH Compound Identifier 65864.

UNSPSC 51282203 Flomoxef is a Commodity code that does not reflect the pharmaceutical procurement activity actually being sourced under it in recent state and local opportunities. The recent opportunities posted under this code involve naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products — none of which are flomoxef-specific pharmaceutical acquisitions. State and local governments using this code designation are sourcing broad pharmaceutical inventories, emergency medical supplies, and pharmacy benefit program support rather than a single narrow antimicrobial product line.

Recent solicitations span state health agencies, county public health departments, municipal fire departments, and multistate cooperative purchasing organizations. Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The City of Tampa issued an IFB on March 25, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a deadline of March 13, 2026; this procurement is designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, serving participating state and local government facilities across Minnesota and Oregon through three authorized wholesalers. The code shows activity across Florida, Texas, and the Upper Midwest, though the misalignment between the code designation and actual scope suggests the code is not an appropriate classification for these pharmaceutical and medical supply procurements.